Many factors must be considered and discussed with women when initiating a contraceptive
method and the risk of venous thromboembolism (VTE) is one of them. In this review, we …

In 2018, the International Council for Standardization in Haematology (ICSH) published a
consensus document providing guidance for laboratories on measuring direct oral …

Objective To compare the impact on thrombin generation of the new combined oral
contraceptive containing 15 mg estetrol and 3 mg drospirenone with ethinylestradiol (30 or …

Purpose Despite considerable advances in recently developed combined oral
contraceptives (COCs), resulting in lower rates of adverse events while maintaining …

Objective This study aimed to determine the effects of estetrol (E4) on hemostasis, lipids,
carbohydrate metabolism and bone turnover in postmenopausal women. Methods This …

From the data in our possession derived from the literature, it has been shown that men
have a high risk and appear to have a specific higher risk of suffering from thromboembolism …

Activated protein C (APC) resistance (APCR) has been identified as a risk factor of venous
thromboembolism (VTE). A mutation at the level of factor (F) V has at first permitted the …

Activated protein C (APC) resistance (APCR) is considered a risk factor of venous
thromboembolism (VTE). The most common genetic disorder conferring APCR is a factor (F) …

Hormonal contraceptives (HC) are widely used among women in reproductive ages. In this
review, the effects of HCs on 91 routine chemistry tests, metabolic tests, and tests for liver …

We read with interest the article of Booyens et al. discussing the risk of venous
thromboembolism (VTE) with hormonal replacement therapy (HRT)[1]. This article nicely …